

Mérieux Equity Partners sells minority stake in Ceva Santé Animale held by its fund Mérieux Participations 3, and reinvests in the company with Mérieux Participations 4

Paris/Lyon – March 31, 2025. Mérieux Equity Partners is pleased to announce that, as part of the renewal of the shareholding structure of Ceva Santé Animale, Mérieux Participations 3 has sold its minority stake in the company. The successor fund, Mérieux Participations 4, has also participated in the transaction, making a new minority investment in the company.

Ceva Santé Animale, headquartered in Libourne (France), is the fifth-largest global player in animal health and the leading independent player. The company develops, produces, and distributes pharmaceutical products and vaccines worldwide to veterinarians, livestock professionals, and pet owners. The company operates in 47 countries and employs over 7,000 people globally. It achieved a turnover of €1.77 billion in 2024.

We have supported this French leader since 2014, initially with the Mérieux Participations 2 vehicle, and then with Mérieux Participations 3 since 2020. We are pleased to renew our confidence in the management team as part of this new transaction, which brings together both the majority of existing investors (including Temasek, Téthys, EMZ, and Sagard) and new investors (including the Institut Mérieux and the investment fund Archimed).

Jean-François Billet, Managing Partner & Head of Buyout, states: "Since our initial investment, Ceva Santé Animale has demonstrated the strength of its business model, the relevance of its strategic choices, and, above all, the remarkable commitment of its management. We are particularly proud to continue backing the growth of Ceva Santé Animale, driven by its very dynamic international development and the quality of its innovations, by providing our full support to Dr. Marc Prikazsky and his team."

Mérieux Participations 3 (vintage 2018, €377m) and Mérieux Participations 4 (vintage 2021, €568m) are the two buyout funds successfully launched by Mérieux Equity Partners since obtaining its AMF approval in 2018. Since then, the team has independently managed, from Institut Mérieux, the investment activities of these funds on behalf of third parties, particularly institutional and private investors.

About Mérieux Equity Partners - www.merieux-partners.com

Founded in 2009, Mérieux Equity Partners ("MxEP") is a leading European healthcare-specialized investment firm, with two dedicated platforms, Venture Capital and Buyout, supporting companies ranging from start-ups to established leaders. Benefiting from a longstanding expertise and a large network, MxEP invests in companies with ambitious growth projects and transformative products or services in healthcare. MxEP is AMF-accredited and currently manages c.€1.5bn of AuM.

List of participants

- **Mérieux Equity Partners** : Jean-François Billet, Quentin de Labarre, Romain Blache



Buy-side advisors

- **DLA Piper** : Sarmad Haidar, Edouard Baladès

Press contacts

- **MHP:** James McFarlane (james.mcfarlane@mhpgroup.com), Matthew Taylor (matthew.taylor@mhpgroup.com)